Vinorelbine – Non-small cell lung cancer

NICE recommendations, summary of meeting discussions, links to additional supporting docs etc.

NICE: Chemotherapy for non-small cell lung cancer (NSCLC) should be considered as an option in patients who are unsuitable for, or considered unlikely to respond to an attempt at curative treatment.

Gemcitabine, paclitaxel, and vinorelbine should each be considered as part of first-line chemotherapy options for advanced (stage III and IV) NSCLC patients. Combination of these three agents individually with platinum-based chemotherapy, where tolerated, is likely to be the most effective approach.

March 2008: The TAG recommended that all oral anticancer medicines identified by the National Patient Safety Agency (NPSA) in the Rapid Response Report “Risks of incorrect dosing of oral anti-cancer medicines” (January 2008), for which there are no locally agreed shared care protocols, are classified as Red (Hospital Only).

Commissioning responsibility of NHS England SCG from April 2013.